Worth Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-100
Closed -$1.29K 346
2023
Q2
$1.29K Hold
100
﹤0.01% 407
2023
Q1
$1.32K Hold
100
﹤0.01% 431
2022
Q4
$1.5K Hold
100
﹤0.01% 417
2022
Q3
$1K Hold
100
﹤0.01% 437
2022
Q2
$1K Hold
100
﹤0.01% 507
2022
Q1
$2K Buy
+100
New +$2.71K ﹤0.01% 482

Other funds holding RIGL

Worth Asset Management's RIGL Position: Q3 2023 in Review

Worth Asset Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2023, closing a stake of 100 shares — an estimated $1.29K sold.

Worth Asset Management first reported a position in RIGL in Q1 2022 and held it in 6 quarters. The position peaked at $2K in Q1 2022. 106 funds tracked by Wall St. Rank hold RIGL as of Q3 2023.

  • Worth Asset Management reported no remaining Rigel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Worth Asset Management sold 100 Rigel Pharmaceuticals shares in Q3 2023, an estimated $1.29K.
  • Worth Asset Management first reported a position in Rigel Pharmaceuticals in Q1 2022 and held it in 6 quarters.
  • Worth Asset Management's Rigel Pharmaceuticals position peaked at $2K in Q1 2022.
  • 106 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2023.

Based on Worth Asset Management's 13F filing for Q3 2023, filed 11 Oct 2023.